Aurisco Pharmaceutical Co., Ltd. was founded in 1998, focusing on the production and sales of complex APIs, FDFs and CRDMO of oligonucleotide APIs. It has been listed on the main board of Shanghai Stock Exchange since 2020 (stock code 605116). The company currently has 3 factories, 6 R&D centers, more than 1,300 employees and around 240 R&D personnel. It takes a leading position in the field of complex synthesis, synthetic biology, oligonucleotide synthesis, photochemistry and other fields and has become a long-term partner of many world-renowned pharmaceutical companies. With international compliant quality system, sufficient production capacity, global sales network, we are able to provide high-quality products and efficient services to customers around the world. Email: info@aurisco.com Website: http://www.aurisco.com/
